Eton rises on commercial availability of its metabolic disorder treatment

Eton Pharmaceuticals

02/02/2024 12:32

** Shares of drug developer Eton Pharmaceuticals  ETON.O 
rise ~3% to $4.74 premarket
    ** Co says its drug Nitisinone for the treatment of
tyrosinemia type 1 (HT-1) will be commercially available
exclusively through Optime Care, a specialty pharmacy
    ** HT-1 is a rare genetic metabolic disorder characterized
by lack of the enzyme fumarylacetoacetate hydrolase (FAH)
    ** Up to last close, stock up 32.2% in the last 12 months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))